More than 50% of American adults suffer from gum recession and now there’s a new, less invasive solution to treat it. For ...

The UAE has approved Tolebrutinib, the world’s first oral treatment for non-relapsing secondary progressive multiple sclerosis (SPMS). Developed to slow disability progression without relying on ...

Professional advice on the at-home and in-office treatments that actually work. By Kari Molvar Hair loss is frustratingly common, affecting more than 80 million people in the United States alone.

Aug 11 (Reuters) - British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority review of gepotidacin, an oral antibiotic to treat sexually ...

The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has adopted a positive opinion on zuranolone (Zurzuvae, Biogen Netherlands BV), the first oral drug to treat ...

Santosh Tadakamadla received National Health and Medical Research Council Early Career Fellowship (APP1161659) from 2019-2023. He is Head of Dentistry and Oral Health at La Trobe Rural Health School ...

All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studying oral Xanamem® vs. placebo for 36 weeks, followed by an open label extension of active Xanamem for up to 24 months ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Oral BI 1815368 from Boehringer Ingelheim aims to ...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY ® ...

Orsini will be the specialty pharmacy partner for Ekterly. KalVista Pharmaceuticals Inc. announced today that the FDA has approved Ekterly (sebetralstat), a novel plasma kallikrein inhibitor for the ...

SHANGHAI, July 2, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today ...